Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages

  Chmiel, Katarzyna D ^a,b   Suan, Dan ^c   Liddle, Christopher ^c,d   Nankivell, Brian ^c,d   Ibrahim, Ramy ^e   Bautista, Charmaine ^f   Thompson, John ^d,g   Fulcher, David ^c,d   Kefford, Richard ^b,c,d,g  

^a Westmead Cancer Care Centre   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e BRISTOL MYERS SQUIBB   (United States)

^f Bristol Myers Squibb ^*  (Singapore)

^g MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; ANOREXIA; ARTICLE; CASE REPORT; COLITIS; DRUG DOSE REDUCTION; DRUG MECHANISM; ENDOCRINE DISEASE; FEVER; HEPATITIS; HUMAN; HYPOPHYSITIS; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MACULOPAPULAR RASH; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PSYCHOSIS; SENTINEL LYMPH NODE; SKIN DISEASE; UVEITIS; VOMITING;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; DRUG-INDUCED LIVER INJURY; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PLATELET COUNT; SURVIVAL RATE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 79952745218     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2206     Document Type: Article

References (13)

1. Sarnaik AA, Weber JS: Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 15:169-173, 2009
2. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
3. National Cancer Institute: Ipilimumab clinical trials. http://www.cancer.gov/ drugdictionary/?CdrID=38447
4. Wing K, Onishi Y, Prieto-Martin P, et al: CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271-275, 2008
5. Friedline RH, Brown DS, Nguyen H, et al: CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421-434, 2009
6. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741-750, 2005 (Pubitemid 46224173)
7. Phan GQ, Weber JS, Sondak VK: CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: Surgical issues. Ann Surg Oncol 15:3014-3021, 2008
8. Chin K, Ibrahim R, Berman D, et al: Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy. Ann Oncol 19:vii244, 2008 (suppl 8; abstr 787P)
9. Di Giacomo AM, Danielli R, Guidoboni M, et al: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297-1306, 2009
10. Beck KE, Blansfield JA, Tran KQ, et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289, 2006 (Pubitemid 46630658)
11. O'Day SJ, Maio M, Chiarion-Sileni V, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 21:1712-1717, 2010
12. Bock HA, Gallati H, Zürcher RM, et al: A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 59:830-840, 1995
13. Harmankaya K, Erasim C, Koelblinger C, et al: Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol [epub ahead of print on July 1, 2010]